Table 5.
Pharmacokinetic parameters of terazosin after i.v. administration of terazosin at a dose of 10 mg kg−1 to rats without (control) and with pretreatment with dexamethasone phosphate or troleandomycin
| Parameter | Control | With dexamethasone phosphate | With troleandomycin |
|---|---|---|---|
| AUC (μg min ml–1) | 430±54.6 | 353±78.6a | 749±177b |
| Terminal t1/2 (min) | 186±31.6 | 191±91.3 | 219±96.3 |
| MRT (min) | 97.5±17.9 | 87.0±88.1 | 201±81.1c |
| Vss (ml kg−1) | 2180±507 | 1600±1960 | 2510±792 |
| CL (ml min−1 kg−1) | 23.2±2.84 | 28.4±6.42a | 13.4±3.26b |
| CLR (ml min−1 kg−1) | 4.63±1.13 | 2.13±1.68a | 1.88±1.45c |
| CLNR (ml min−1 kg−1) | 19.8±2.85 | 25.7±5.20c | 11.5±2.45b |
| Ae0–24 h (% of terazosin dose) | 20.4±3.11 | 9.70±3.41b | 16.6±7.53 |
| GI24 h (% of terazosin dose) | 0.148±0.114 | 0.208±0.289 | 1.01±1.05a |
Abbreviations: Ae0–24 h, percentage of dose excreted in 24 h urine; AUC, total area under the plasma concentration–time curve from time zero to time infinity; CL, time-averaged total body clearance; CLR, time-averaged renal clearance; CLNR, time-averaged nonrenal clearance; GI24 h, percentage of dose recovered from the entire gastrointestinal tract (including its contents and feces) at 24 h; MRT, mean residence time; t1/2, half-life; Vss, apparent volume of distribution at steady state.
Data are expressed as mean±s.d. (control, n=8; with dexamethasome phosphate, n=7; with troleandomycin, n=7). Significant difference from control,
P<0.05,
P<0.001 and
P<0.01.